Danaher (NYSE:DHR) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Key Points

• Robert W. Baird raised Danaher’s price target from $246 to $254 and maintained an “outperform” rating, implying approximately 8.55% upside from the current price.
• Danaher reported quarterly EPS of $2.11, beating the $1.92 consensus estimate, while revenue increased 8.3% year over year to $6.55 billion, roughly in line with expectations.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and average price target of $235.86; institutional investors own approximately 79.05% of the stock.

Danaher (NYSE:DHR - Get Free Report) had its price objective increased by stock analysts at Robert W. Baird from $246.00 to $254.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the conglomerate's stock. Robert W. Baird's price target points to a potential upside of 8.55% from the stock's current price.

DHR has been the subject of several other reports. Weiss Ratings raised shares of Danaher from a "hold (c-)" rating to a "hold (c)" rating in a report on Wednesday, September 16th. Evercore reaffirmed an "outperform" rating and issued a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Guggenheim boosted their target price on shares of Danaher from $200.00 to $250.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Stifel Nicolaus lowered their price target on Danaher from $260.00 to $220.00 and set a "buy" rating on the stock in a report on Wednesday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $235.86.

Danaher Price Performance

NYSE DHR opened at $233.99 on Thursday. Danaher has a one year low of $160.93 and a one year high of $242.80. The stock has a 50-day moving average of $215.25 and a 200 day moving average of $196.84. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company has a market capitalization of $164.49 billion, a price-to-earnings ratio of 41.56, a PEG ratio of 2.82 and a beta of 0.76.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.19. The business had revenue of $6.55 billion for the quarter, compared to analysts' expectations of $6.56 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.89 EPS. On average, sell-side analysts forecast that Danaher will post 8.53 EPS for the current year.

Institutional Trading of Danaher

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of Danaher in the 2nd quarter worth $10,492,520,000. Jupiter Topco LLC purchased a new stake in Danaher in the second quarter worth about $1,456,317,000. Generation Investment Management LLP purchased a new stake in Danaher in the second quarter worth about $1,287,949,000. Bank of America Corp DE bought a new position in shares of Danaher in the second quarter worth about $993,846,000. Finally, Legal & General Group Plc bought a new position in shares of Danaher in the second quarter worth about $801,056,000. 79.05% of the stock is currently owned by institutional investors.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported adjusted earnings of $2.11 per share, above the $1.92 analyst consensus and up from $1.89 a year earlier. Revenue rose 8.3% to $6.55 billion, narrowly below or effectively in line with the $6.56 billion estimate. Danaher Reports Third Quarter 2026 Results
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, signaling confidence that improving customer demand and operating performance will continue. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: Biotechnology was a key growth driver: orders increased at a mid-teens rate, while stronger profitability in the segment helped produce the earnings beat. Management also cited improving trends across several end markets. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Management highlighted artificial-intelligence capabilities as a potential long-term growth opportunity in drug discovery, describing Danaher as having the foundational technologies—or “building blocks”—to participate in the market. Danaher says it has building blocks for AI drug discovery growth
• Neutral Sentiment: The acquisition of Masimo helped offset weaker respiratory diagnostic sales, suggesting integration benefits but also continued softness in parts of the diagnostics portfolio. Danaher’s Masimo acquisition offsets drops in respiratory diagnostic sales
• Negative Sentiment: Revenue did not materially exceed expectations, and the ongoing CEO transition could create uncertainty around execution and Danaher’s strategic priorities despite the stronger outlook. Danaher drops after Q3 revenue miss amid CEO transition

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.